Aclaris Therapeutics (ACRS) Preferred Stock Liabilities (2014 - 2015)
Aclaris Therapeutics' Preferred Stock Liabilities was $78.31 million in Q3 2015.
Powered by 
Analysis
Aclaris Therapeutics (ACRS) Preferred Stock Liabilities (2014 - 2015) Analysis & Trends
At the end of FY2014, Preferred Stock Liabilities at Aclaris Therapeutics came in at $36.68 million, up 59.5% from FY2013.
- In earlier years, Preferred Stock Liabilities was $23 million in FY2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | - |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | - |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | - |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | - |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | - |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | - |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | - |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | - |
| 10 | Aclaris Therapeutics | 625.92 Mn | 223.91 Mn | 1.29 Mn | - |
API Access
Aclaris Therapeutics Preferred Stock Liabilities API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=ACRS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "preferred-stock-liabilities", "ticker": "ACRS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=ACRS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();